

Hereford Funds **DSM US SMID Cap Growth Fund** February 2008

February 2008 Investment Review

The Hereford/DSM SMID Cap Fund declined (2.0%) for the month of February compared to a (2.0%) decline in the Russell 2500 Growth and a (3.3%) delcine in the S&P500. The majority of the portfolio is presently invested in the health care, technology, professional services, energy services and industrial sectors. As was the case for the prior three quarters, the portfolio holdings in the fourth quarter continued to generate over twenty percent revenue and earnings growth. The weighted portfolio is presently valued at 17x 2008 earnings. We continue to believe that our SMID portfolio remains very attractively valued in the current investment environment.

There are a number of cross-currents in the financial marketplace today. While the credit quality of financial institutions is a central issue, the financial stability of the municipal bond and mortgage reinsurance companies is also front-and-center. Additionally, the American economy has slowed and could enter a recession in the near future. The global economy has slowed as well, both in Europe and in Southeast Asia. In response, the Federal Reserve has reduced short-term rates to encourage economic growth and thereby avoid a recession. Finally, there have also been some recent economic reports that indicate an up-tick in inflation.


We have recently purchased ten new positions. Expeditors International and C.H. Robinson are two of the leading freight forwarders in the world, although C.H. Robinson is more North American-based and Expeditors International is more Asia-focused. We purchased Autodesk and Ansys, both of which provide engineering design and simulation software products. We purchased Lenovo, one of the leading global suppliers of personal computers. Amcol is a leading global producer of materials for moisture barriers in commercial and industrial applications. ARM Holdings is a leading licensor and producer of RISC-based microprocessors. Cubist Pharmaceuticals develops and sells a powerful anti-infective, primarily for the hospital environment. Dynamic Materials provides explosives for high technology metal cladding, as well as sophisticated welding technologies. All of the companies mentioned above we have owned in the past, with the exception of Dynamic Materials.

Key information

NAV A Shares (29/02/08): \$84.84 Total Fund Size: \$3.3 Million Strategy Assets: \$15.7m^(a) Fund Launch Date: 29-Nov-07

Monthly Performance (%)

Hereford Funds NAV Russell 2500 Growth ^(b)	Jan (12.1) (8.2)	Feb (2.0) (2.0)	Mar	Apr	Мау	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD (13.8) (10.0)
Period Performance (%)	Since Inception 01/01/03												
	YTD	2007	2006	2005	2004	2003		Cumula	tive	Annu	alised		
DSM SMID Cap/Hereford SMID Returns ^(c)	(13.8)	21.3	16.5	16.4	3.6	46.4		115	5.1	16	.0		
Russell 2500 Growth ^(b)	(10.0)	9.7	12.3	8.2	14.6	46.3		101	.0	14	.5		





Top Ten Holdings	% NAV	Sectoral Breakdown	% of assets	
Ion Geophysical	4.4%	Health Care	28.9%	
Varian Medical Systems	4.1%	Informational Technology	26.7%	
Hologic	3.9%	Energy	14.1%	
Satyam Computer Services	3.9%	Financials	6.7%	
Chart Industries	3.9%	Consumer Discretionary	5.4%	
Sei Investments	3.7%	Industrials	14.3%	
Core Laboratories	3.7%	Materials	1.7%	
Nobel Biocare Holdings	3.5%			
Zoll Medical	3.3%			
Fmc Technologies	3.2%			

Investment Objective

The investment objective of the sub fund is to provide capital appreciation principally through investments in US-based growing corporations with market capitalizations generally between 300 million and 10 billion dollars. These companies are chosen for their growth prospects, attractive returns, solid business fundamentals and intelligent management. Companies invested in will often have higher revenue and earnings growth rates and less "sell-side" research coverage than comparable larger capitalization corporations. The sub fund may, on an ancillary basis, invest in US-based companies with higher or lower market capitalizations as well as in non-US based companies. The sub fund may invest in American Depository Receipts and American Depository Shares. The reference benchmark for this strategy is the Russell 2500 Growth Index.

		Since Inception					
Fund Codes (Share Class A)		Risk Profile	DSM US SMID	DSM SMID	R2500 Growth		
Bloomberg ISIN Reuters Sedol Valoren WKN	DSMUSMA LX LU0327605118 LP65102019 B28TM17 3504786 A0M58X	Volatility Sharpe Ratio Information Ratio Tracking Error Beta Alpha	n/a n/a n/a n/a n/a	14.9 0.9 0.2 7.4 0.9 2.5	14.2 0.8		
Fund Details	Nomoox	Alpha	n/d	2.0			
Dealing Day Dividends Investment Manager Promoter Authorized Corporate Director Custodian Legal Advisers Auditor	Daily None - income accumulated within the fund DSM Capital Partners LLC, 320 East Main Street, Mount Kisco, NY 10549, USA VP Bank (Luxembourg) S.A., 26 Avenue de la Liberté, L-1930 Luxembourg VPB Finance S.A., 26 Avenue de la Liberté, L-1930 Luxembourg VP Bank (Luxembourg) S.A., 26 Avenue de la Liberté, L-1930 Luxembourg Elvinger, Hoss & Prussen, 2 Place Winston Churchill, L-1340 Luxembourg Deloitte,560 Rue de Neudorf, L-2220 Luxembourg						
Annual Management Charge							
Share Class A Share Class B Share Class C Share Class D	1.25% 0.25% + 20% performance fee on outperformance vs US T-Bill with HWM 1% + 20% performance fee on outperformance vs US T-Bill with HWM 1.75%						
Minimum Investment							
Share Class A&B Share Class C&D	\$100,000 initial / \$10,000 subsequent \$10,000 initial / \$1,000 subsequent						
Order Transmission / Information Original Applications to:		Subsequ	ent Applications O	nly Via Facsim	ile:		
VPB Finance S.A. attn. Fund Operations / TA-HFF P.O. Box 923 L-2019 Luxembourg or, for transmissions via courier service, 26, avenue de la Liberté, L-1930 Luxembour	g	Fax : (· Tel: (·	nce S.A. I Operations / TA-Hf +352) 404 770 283 +352) 404 770 260 «funds.info@vpbank				
(a) This refers to the total assets invested in the ref	erence strategy managed l	by the Investment Manager					

(a) This refers to the total assets invested in(b) Total return including dividends

(c) Total return including dividends
(c) Data and graph depict DSM Composite through November 2007 and Hereford Funds DSM US SMID Cap Growth Fund Class A thereafter. Historical gross performance of DSM SMID Cap Composite returns (the Reference Strategy) minus modeled fee and expense typical of Hereford Funds DSM US SMID Cap Growth Fund Class A (1.25% fee + 0.25% expense). Fund follows same strategy. Performance presentation incomplete without accompanying footnote: as shown at dsmcapital.com.

This document is for information purposes use only. It is neither an advice nor a recommendation to enter into any investment. Investment suitability must be determined for each investor, and this fund may not be suitable for all investors. This information does not provide any accounting, legal, regulatory or tax advice. Investors should consult professional advisers to evaluate this information. An investment should be made only on the basis of the Prospectus, the annual and any subsequent semi-annual-reports of HEREFORD FUNDS (the "Fund"), a société d'investissement à capital variable, established in Luxembourg and registered under Part I of Luxembourg law of 20 December, approved by the Commission de Surveillance du Secteur Financier (CSSF). These can be obtained from [the Fund, 26, avenue de la Liberté, L-1930 Luxembourg or from VPB Finance S.A., 26, avenue dela Liberté, L-1930 Luxembourg and any distributor or intermediary appointed by the Fund]. No warranty is given in whole or in part, regarding performance of the Fund. There is no guarantee that its investment objectives will be achieved. Investors should be read in conjunction with the most recent publication of the Prospectus of the Fund. While great care is taken to ensure that this information is accurate, no responsibility can be accepted for any errors, mistakes or omission or for future returns. This document is intended for the use of the addressee only and may not be reproduced, redistributed, passed on or published, in whole or in part, for any purpose, without the prior written consen of HEREFORD FUNDS. Neither the CSSF nor any other regulator has approved this document. Full details of the investment policy and objectives are stated in the Prospectus.